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ABSTRACT
Little is known about chronic obstructive pulmonary disease (COPD) patients experience with
home-based health treatments, which are currently rapidly evolving. A previous randomized
controlled trial investigated the use of long-term oxygen enriched high flow nasal cannula
(HFNC) treatment at home. The aim of this study was to explore COPD patients’ experience
using home HFNC treatment. Patients in this qualitative study were included from the previous
RCT. All patients used long-term oxygen therapy and HFNC, the latter as a primarily nocturnal
add-on. Data were collected using semi-structured interviews focused on four themes:
‘Description of daily use’, ‘Experienced changes’, ‘Treatment benefits and disadvantages’ and
‘User-friendliness’. The interviewer played an encouraging, non-normative neutral facilitator role
in order to give the participants possibility to explain themselves as fully as possible.
Participants were recruited until themes were saturated. A total of 12 patients (5 males, 7
females) and 8 relatives participated. Six themes were identified as important to patient adher-
ence: Perceived lower work of breathing; reduced symptoms; improved quality of sleep;
increased activity of daily living; feeling safe; technology use. The results increase our know-
ledge of patient experience of using HFNC for home treatment, which improved the patients’
experience through reducing symptoms and increase the activity of daily living. Furthermore,
they substantiate the necessity of perceived usefulness and ease of use as important factors for
adherence to treatment.
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Chronic obstructive pulmonary disease (COPD) is a com-
mon, preventable and treatable disease characterized by per-
sistent respiratory symptoms and airflow limitation. Some of
the most common respiratory symptoms are dyspnea, cough
and/or sputum production [1–4]. Furthermore, quality of
life (QoL) is impaired in COPD patients and it deteriorates
with increasing severity of disease [5,6].
Although preventable and treatable, COPD is a slow pro-
gressive chronic disease. Patients must learn to live with
symptoms that become more severe as the disease progresses
[1,2]. Pinnock et al. reported, that COPD patients described
their disease as ‘a way of life’ [7]. This is especially relevant
with disease flare ups (exacerbations), characterized by wor-
sening of symptoms that can lead to substantial morbidity
and mortality [3,8]. COPD exacerbations also contribute to
disease progression, therefore the main goal of treatment is
to reduce exacerbations and relieve symptoms [3]. In late
stage disease patients may suffer from chronic respiratory
failure, due to disturbances of gas exchange caused by
impairments in either oxygenation or removing carbon
dioxide [9]. Data on the prevalence of Chronic hypoxemic
failure are sparse, however, the incidence of COPD patients
on long-term oxygen therapy (LTOT) in Denmark was rela-
tively stable between 2001 and 2010 [10].
LTOT is an established and well documented treatment
for COPD patients with chronic hypoxemic respiratory fail-
ure and has been shown to increase survival [11,12]. Despite
this, a review by Katsenos et al. showed that only 45–70% of
COPD patients are adherent to optimal LTOT [13]. A pos-
sible explanation could be side effects caused by LTOT such
as nasal dryness, nasal bleeding, dizziness, impaired taste
and olfaction, and unpleasant cosmetic effects [13,14].
Another reason for cessation/discontinuing treatment might
be a perceived lack of substantial benefits of treatment [13].
Development in home treatment for COPD has evolved
over the last two decades with technologies like telemedicine
and noninvasive ventilation [15]. A recent published RCT
study including 200 COPD patients investigated a new
home treatment for COPD patients with chronic hypoxic
failure. One hundred patients in the intervention group had
a nasal high-flow humidifier device installed at home for
complementary use with their standard LTOT. This device
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can deliver 37C fully humidified respiratory gases between 10
and 60 l/min, with the ability to add supplementary oxygen as
required. The above mentioned RCT study presented signifi-
cant improvements with using high flow nasal cannula
(HFNC), including a significant reduction in the number of
exacerbations, a decrease in dyspnea (mMRC score) and a posi-
tive effect on QoL [16].
Despite the significant treatment effect, half of the
patients discontinued treatment within the study period
[16]. For future home treatment, it is therefore important to
obtain a better understanding of patients’ perspective and
the important issues related to treatment adherence.
As health technology for home treatment is evolving, it is
important to acknowledge possible obstacles with treatment
and meet patients’ needs in order to ensure patients’ adher-
ence to treatment [17,18]. Therefore, knowledge in patients’
experience is of great value for implementing treatment with
health technology at home.
The objective of this present study was to explore COPD
patients’ experiences with HFNC at home. We focused on




The methodological approach of the study was interpretive
descriptive inspired by hermeneutics [19]. The focus of the
study was on the patients’ perspectives and descriptions of
their experiences living with HFNC at home. The study used
qualitative semi structured interviews to obtain rich and
nuanced descriptions of patients’ experiences. This method-
ology was adopted as it seeks to understand and explore based
on the individual’s own experience [19]. The reporting of the
study is in accordance with the Consolidated Criteria for
Reporting Qualitative Research (COREQ) [20].
Participants
The participants were purposively and conveniently sampled
from the Department of Respiratory Diseases at Aalborg
University Hospital in Denmark. All included patients were
patients with COPD and chronic hypoxic failure who had
been enrolled in the former HFNC study [16]. At time of
inclusion, they were treated with HFNC for a minimum of
4 h/day. The length of use ranged from two to 45months.
At the final 12months visit in the HFNC study, 12
patients were informed and invited to participate in a qualita-
tive study concerning their experiences with HFNC home
treatment by the study nurse. Nine patients from the former
intervention group and three patients from the control group
were asked for permission to contact them by phone, when
the study had been described and approved. Patients from
the control group were allowed to start HFNC treatment at
the completion of their 1 year within trial period. All patients
gave consent. When ready to interview, the study nurse con-
tacted the patients and repeated information and aim of the
study. If patients still consented, the interview took place
either at the hospital or in the patients’ homes. Patients were
also given the option to invite their relatives to participate.
All 12 patients, five men and seven women participated. By
patients’ choice, eight interviews took place in patients’ homes
and four took place at the hospital. In total eight relatives
participated in the interview – one daughter, two husbands
and five wives. The interviews were carried out from March
2016 till December 2016. Characteristics of patients and the
number of relatives participating are presented in Table 1.
Data collection
Data were collected using interviews [19]. All interviews
were conducted by the first author. The interviewer played
an encouraging, non-normative neutral facilitator role in
order to allow the participants the possibility to explain
themselves in their own words as fully as possible [19]. To
ensure consistency in the interviews a semi-structured inter-
view guide was developed with open-ended questions. The
guide was pilot tested on two COPD patients, and after-
wards the first and last author reconsidered content and
process. No changes were made, and the interview guide is
available in Table 2. The semi structured interviews allowed
participants to bring up topics or express thoughts that they
considered important for their experiences, which were fol-
lowed up by additional questions if required to fully under-
stand the participants perspective.
Table 1. Patient characteristics.
Participating patients HFNC treatment Participating relatives
Study ID Age/sex Domiciliary status FEV1 (%)
a PaCO2 (kPa)
a Length of use (months) Mean use (h/day) Time of use Relatives participating
PP 1 52/F Living with family 27 6.50 42 9 D/N None
PP 2 75/M Partner 32 5.23 33 9 N Wife – PR 2
PP 3 60/F Living alone 18 6.90 15 7 D/N Daughter – PR 3
PP 4 68/M Partner 19 5.54 13 10 N Wife – PR 4
PP 5 72/F Partner 12 6.09 24 10 N Husband – PR 5
PP 6 65/F Partner 28 6.99 13 8 N Husband – PR 6
PP 7 72/M Partner 17 5.56 12 9 D Wife – PR 7
PP 8 69/F Partner 26 6.27 9 7 N None
PP 9 74/M Partner 26 4.76 42 10 N Wife – PR 9
PP 10 67/F Partner 36 6.34 45 7 D None
PP 11 55/F Partner 17 6.26 2 7 N None
PP 12 84/M Partner 41 5.23 26 9 N Wife – PR 12
Note: PP, participating patients; PR, participation relatives; D, daytime; N, night time.
aLungfunction (FEV1) and arterial puncture (PaCO2) measured at treatment start.
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The interviews lasted from 17 to 44min and were audio-
taped and transcribed verbatim by the first author. The tran-
scriptions of the interviews were completed shortly after the
interviews were conducted to determine whether data satur-
ation was reached. As a result, the number of twelve interviews
was not determined in advanced but proved to be an adequate
number in terms of data saturation as no new insights or
nuances emerged during the last interviews [19]. The transcrip-
tions resulted in a total of 89 pages (Calibri size 11).
Ethics
The study was approved by the Danish Data Protection
Agency (number 2008-58-0028; 2016-185). Qualitative studies
do not need approval from The Ethics Committee (http://
www.nvk.dk). All participants were given both oral and writ-
ten information about the study and informed written con-
sent was obtained from all participants before participation.
Confidentiality and anonymity were secured. It was empha-
sized that participants could withdraw consent at any time
without consequences for current or future treatment.
Data analysis
In order to search for meaningful patterns (themes) across
the interviews, thematic analysis was performed [19].
Thematic analysis is a method for identifying, analyzing and
reporting themes within qualitative data, it is suitable for
identifying meaningful themes and patterns across the expe-
riences of patients regarding living with HFNC at home. In
accordance with the adaptive approach used in the study,
the thematic analysis process was an iterative process. The
themes were identified from the data and involved the fol-
lowing steps. The first step of the analysis involved initial
reading and precoding in order to get a sense of all data
material and to comprehend the overall meaning of the par-
ticipants’ statements. Preliminary categories and themes
were subsequently identified based on the initial coding. The
themes were reviewed to check whether they adequately cap-
tured the contours of the coded data, which became the
basis for theoretical interpretations [19]. The final step in
the data analysis involved defining and naming the themes
and reporting of the analysis [19].
Results
A total of 12 patients and 8 relatives participated. HFNC
was used as an add-on treatment for a mean of 8.5 h/day
(self-reported use). The majority of patients were living with
their spouse/family, only one patient lived alone. Lung func-
tion (FEV1%) at treatment start ranged between 12 and
41%. Furthermore, hypercapnia, defined as PaCO2> 6.0 kPa
was identified in 7/12 (58%) of participants. Patient charac-
teristics are summarized in Table 1.
Six themes emerged from the interviews, and these iden-
tified that COPD patients and relatives often had the same
experiences with HFNC treatment at home. These themes
included: ‘Perceived lower work of breathing’, ‘Improved
quality of sleep’, ‘Increased activity of daily living’, ‘Reduced
COPD symptoms’, ‘Feeling safe’ and ‘Technology use’
(Figure 1). The findings in each theme are described in the
following section substantiated by quotations from inter-
views with patients and their relatives.
Perceived lower work of breathing
A common experience among patients was that they found
it easier to breath and felt more relaxed when using HFNC.
Normally their workload of breathing was high, which
diminished their energy reserves for other daily living activ-
ities. As one patient said:
It’s just getting easier to breathe. Normally, I have to exert myself
breathing. I don’t have to with the humidifier on. (PP 12)
When patients feel the difference, it can encourage them
to continue their treatment and it reduces their anxieties.
Breathing is something most of us take for granted and do
automatically. This is not the case for patients with severe
COPD. Breathing is on their mind 24/7, but this also changed
with the HFNC treatment according to the patients:
I don’t have to think the same way about breathing. I’m more
relaxed. (PP 6)
Table 2. Semi-structured interview guide.
Themes Research questions
Description of daily use How does the patient use the high-flow humidified oxygen on a daily basis?
Experienced changes Did the patients physical, mental and social wellbeing change during the treatment with HFNC?
Treatment benefits and disadvantages Which pros and cons does the patient experience with the treatment?













lower work of 
breathing
Figure 1. Six themes emerged from the interviews.
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The fact that the HFNC treatment allowed them to relax
had a great influence when they go to bed at night. One
patient emphasized:
I’m much more relaxed. I spend much less time trying to
breathe properly. For instance, when I go to bed at night; earlier
I spent a lot of time to get relaxed, I don’t anymore. I can
simply just go to bed, lie down with myAirvo on, and I’m
relaxed immediately. (PP 1)
Leading on to the next theme ‘Improved quality of sleep’,
another patient expanded on her experiences:
I fall asleep faster, maybe because I’m more relaxed. Before I
could lie awake for hours, not able to fall asleep. (PP 5)
Improved quality of sleep
The HFNC treatment resulted in a better sleep for most of
the patients, as they found it easier to fall asleep, possibly
due to the reduced work of breathing. One wife said of her
husband’s sleep:
I think he sleeps better, after he began the treatment. His sleep
is calmer, and he sleeps longer than before. (PR 2, wife)
Another factor that improved the patients’ sleep was hav-
ing less interruptions during the night. This might be due to
less airway dryness, because of the humidification and the
perception of a calmer and easier breathing. Their usual
oxygen treatment is not humidified, so it is cool and dry,
which causes some patients to wake up with a feeling of
dried out airways. Several patients reported that they used
to drink water during the night, which could also result in
the need for extra toilet visits. All these interruptions can
influence the quality of their sleep.
She never complains about dryness anymore, nor is she drinking
water during the night as she used to do. (PR 5, husband)
Another common interruption during sleep was patients
waking up because they were short of breath. Many patients
were in the habit of waking up and sitting on their bedside
several times a night to catch their breath. Some patients
also needed to use their bronchodilators during the night.
I think he sleeps better, because he doesn’t rouse. He used to sit
on his bedside to catch his breath several times during the
night, he doesn’t do that anymore. (PR 9, wife)
Being married to a patient with a chronic respiratory
condition also disturbed the sleep of the spouse. They are
constantly listening to their partners breathing, to check if
they are breathing properly. Amelioration of the patients
sleep also results in improved sleep quality for the spouses.
When the spouses got a good night’s sleep their resourceful-
ness during the daytime increased.
I also get a better night sleep, when I know my husband is calm
and at rest. (PR 12, wife)
Increased activity of daily living
A better sleep can positively influence their level of daily
activity. After a good night sleep with HFNC, they felt more
rested in the morning. Waking up more energized had a
positive effect on their mood and it gave everyone a better
start to the day.
When he wakes up in the morning, he tells me that he is feeling
so well, he is in a better mood. It’s like he has got more energy.
(PR 9, wife)… …That’s right, waking up, I feel like a world
champion, like I can do everything… (PP 9)
I feel, I have a surplus on energy, and when you do that, it
makes you happier. (PP 1)
The increased energy level also affects the patients’ ability
to eat. Many COPD patients struggle to maintain a stable
weight, due in part, that even chewing and digesting food
can cause breathlessness. One patient experienced a weight
gain after he started the HFNC treatment.
Before he had trouble gaining weight, the weight only went
down. Since he got the humidifier, he gained 5 kilos. It might
have been the treatment that gave him more energy to eat. (PR
4, wife)
Another patient and her spouse described a change in the
consistency of food she could eat.
Previously she didn’t have the energy to chew meat, vegetables,
and she was primary eating blended food and yoghurt. Now she
can eat thick slices of bread with cheese, and I don’t have to
mash her potatoes anymore. (PR 5, husband)
When patients are able to eat the same food as the rest
of the family it has a positive impact on their social life and
may lead to patients going out more. In some countries, the
socializing culture often includes dining or drinking, which
can be one of the reasons why COPD patients stay at home.
Eating simply takes too much of their energy, so they are
too breathless to talk and socialize while dining. Feeling
more energized, several patients explained how they were
able to invest more energy in social and physical activities.
I started riding my bike again. When I’m biking, I feel I breathe
more freely than I used to. (PP 11)
I’m getting out more… seeing friends. Today I can take my bike
and go for coffee at a friends’ house or meet up in town on a
cafe. I didn’t do that before. (PP1)
The fact that patients did have more energy to socialize
were also noticed by their relatives and played an important
role to the families.
She’s has gained more energy, that’s for sure. She has been out
and about more and even participated in birthday parties; she
hasn’t done that in years. (PR 3, daughter) … . that’s right, it’s
like I have more zest for life… .or feel more encouraged. (PP 3)
The majority of patients used HFNC at night, but they still
felt it affected their activity levels during the day. One patient
also described how she used it extra hours during the day to
gain more energy when she had a social event at night.
Despite an increased level of energy, the social activity
level remained unchanged for two patients. They argued
that the reason for this was a feeling of being stigmatized
when going out with their portable oxygen equipment. Even
though they felt more energized when using HFNC treat-
ment, they still preferred staying at home. Conversely,
another patient felt the way people looked at her had
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changed after starting the HFNC treatment. Her breathless-
ness had decreased, and she explained:
Earlier I felt that people were staring after me, I don’t
experience that at all today. (PP 1)
Reduced COPD symptoms
This theme describes the participants’ experiences of airway
symptoms (i.e. cough, sputum, chest tightness and dyspnea)
before and after home HFNC treatment. The symptoms in
the morning were the primary focus, as both patients and
relatives reported positive changes. Prior to HFNC treat-
ment, most patients said it was normal to start their day
coughing. They spent a great deal of time and energy every
morning clearing their airways of thick and viscous sputum.
Some of the treatments benefits they all experienced were
significantly less coughing and sputum production.
It’s been easier to cough and get rid of sputum after I’ve got the
humidifier. In the past, I would use a lot more effort and energy
on coughing it up. (PP 11)
Earlier, especially in the morning, I had this long, thick mucus,
that I couldn’t get rid of. I don’t have that anymore. (PP 12)
HFNC treatment resulted in patients experiencing consid-
erably less cough and sputum symptoms. Another symptom
that ameliorated was dryness in both the mouth and air-
ways. Prior to HFNC treatment, all patients described prob-
lems with dried out airways.
Waking up, I feel much better now. Earlier I woke up
completely dried out in my throat. I never feel this dryness
anymore. (PP 9)
Before I got the humidifier, I never left home without a lip
balm. I have two unused in the closet, they haven’t been used
since. So, in that way it’s been really good. (PP 12)
Reduced airways dryness also seemed to improve
patients’ ability to taste and smell. One participant used to
work as a chef. For him an important effect of the HFNC
treatment was regaining his ability to smell and taste.
One of the first things I noticed after starting the treatment was
that I got my taste and smell back. After that the joy of cooking
came back. (PP 2)
I actually think I got my taste and smell back. It’s been gone for
years, but it’s back now. (PP 5)
Being treated with HFNC truly reduced their airway symp-
toms. This agrees with the results from the RCT study which also
demonstrated that patients treated with HFNC had significantly
fewer exacerbations than those treated with LTOT alone [16].
Patients and relatives also noticed the decrease in exacerbations.
The number of exacerbations has decreased enormously. He only
had six this year, earlier he had one each month. (PR 4, wife)
It’s great that I don’t have any infections. I picked up
some antibiotics nine months ago, but I haven’t taken any of
them yet. (PP 6)
Feeling safe
One patient had not felt her symptoms had changed, but in
spite of that she had continued to use the HFNC humidifier
every day for 45months. To further understand her reasons
for continuing the treatment, she was asked to elaborate.
She explained the importance of feeling that you are taking
charge and responsibility of a therapy to ameliorate your
condition. Another reason for being compliant was the
belief in the treatment effect. At each study visit, an arterial
puncture was taken both on LTOT, and then after 30min
HFNC treatment [16]. Many COPD patients are already
familiar with the risk of hypercapnia when treated with
LTOT, and they are therefore paying attention to the blood
gas results. In this case, the patient’s knowledge of the posi-
tive effects of HFNC treatment in lowering her arterial CO2
levels encouraged her to be persistent.
I hold on to the results from the blood samples. When you can
see, that it helps after just 30min treatment, I believe that it
helps. And if not, I can say that I have done something. The
humidifier makes me feel safe. It’s the feeling of being able to
do something yourself. (PP 10)
Besides her belief in the treatment, she described the
importance of being responsible for doing something, kept
her safe. Another patient supported this feeling of safety.
Having the equipment at home gave them a kind of reassur-
ance that also had benefits for their relatives.
I feel safer having it. I don’t panic as before when I get short of
breath which is an important factor I think. (PP 9) … .and that
feeling of safety also affects me. (PR 9, wife)
Technology use
This theme describes patients’ use and experiences with the
equipment. At inclusion, patients were encouraged to use
HFNC approximately 8 h/day preferably during the night.
All participants in this study were adherent to HFNC treat-
ment which they used between 7 and 10 h/day. The majority
of patients (8/12) only used HFNC at night during sleep,
two patients only used it during the day, and two patients
used it both day and night. One of the day only users felt it
was inconvenient to use the device at night.
I think it’s too much of a hassle and there is also a bit of noise.
I think I could get used to it at night, but my wife has to
endure it too. (PP 7)
When treating patients at home it is important to include
the relatives’ perspective on technology acceptance. It is possible
that developing the habit of using HFNC was easier for the
patient, who felt the improvements on their wellbeing, while
their spouse might be more sensitive to the device noise when
going to sleep while not getting any improvement in wellbeing.
Disadvantages with daytime use was described by some
patients and were mainly related to mobility challenges.
Often treatment was interrupted during the day due to other
activities, and for some patients this may have resulted in
not resuming the therapy afterwards.
There are small disadvantages… you have to disconnect when
going to the toilet for instance, and sometimes I forget to put it on
afterwards, because I went on doing something else instead. (PP 3)
It’s like you are locked, you can’t just get up and walk. I have to
be next to the machine. (PP 9)
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The humidified air was delivered to patients at a tem-
perature of 37 C, which was quite different from their usual
LTOT. The warmth was seen as both an advantage and a
disadvantage. One patient described the device as ‘a warm
friend’ (PP 5) and another experienced trouble adhering to
therapy in summer when the weather was warmer (PP 10).
On the other hand, patients described the benefits of warm
air, with one patient saying:
The heat is an advantage. It also helps on my arthritis. (PP 4)
and another patient described:
Sometimes I actually long for it. (PP 8)
Both patients and relatives described the equipment as
simple to use even for people without technical skills. The
device settings were locked, which meant that patients could
not change the flow rate without consulting their health care
professional and technical staff. This made the treatment
manageable and safe for everyone.
The ease of use is high and therefore suitable for people without
technical skills. You can’t change the settings or break anything. (PP 9)
The low complexity of the device also made the adaption
to treatment easy. Treatment became a habit for most
patients, and they used the device continuously. Some
adapted to it very quickly, others struggled more in the
beginning, especially using the nasal cannula.
You just have to get used to the nasal cannula… getting it
attached correctly. I did learn it along the way, so today it’s not
a problem. But to begin with it could be a bit annoying. (PP 4)
After getting used to treatment, one wife described how
her husband had almost developed an addiction to treatment.
I would almost say, that you are addicted to it. (PR 9, wife)
Being almost dependent to treatment also resulted in a
number of patients taking their HFNC device when they
went on holidays or weekends away. As one patient said:
I always bring it to our summer residence. It’s become like… I
can’t do without it. (PP 5)
Another patient described her negative experiences after ceas-
ing treatment for just a couple of days. These experiences of treat-
ment benefits clearly encouraged patients to continue treatment.
I didn’t sleep with it for two nights, and I certainly felt a
difference. I had more trouble breathing and getting rid of
mucus. The worsening also lasted during daytime, so it’s
obviously doing something. (PP 11)
Discussion
Main findings
The aim of this study was to explore COPD patients’ experi-
ences with HFNC at home by focusing on descriptions of
use, experienced changes, pros and cons and ease of use of
the device. Six themes were identified, and the findings
highlights the importance of treating COPD symptoms
which have a crucial and negative impact on physical, social
and mental factors. Nearly all patients and relatives
described an improvement in symptoms after initiating
HFNC, primarily a reduction or elimination of cough/mucus
and a reduction of dyspnea. As a consequence of symptom
reduction patients experienced improved sleep, resulting in
more energy for daily activities – both of social and physical
nature. All patients found the device easy to use, but
the importance of good information about how to use the
device and nasal cannula was also emphasized. Both the
feeling of symptom relief and the perceived ease of device
use was a strong motivator for treatment adherence.
Interpretation of findings in relation to previously
published work
Poor quality sleep for COPD patients has previously been
described [1,21–23]. In one study that included 2800
patients from five European countries, Price et al. found
that 78% of the patients reported nighttime disturbance
[21]. Previous research reported a much greater likelihood
of sleep disturbance amongst COPD patients with cough
and other nighttime symptoms, such as wheezing and short-
ness of breath, which substantiates the findings in this study
[2,21–23]. With HFNC treatment reducing the COPD
patients’ perceived work of breathing and symptoms, the
participants in this study experienced a better quality of
sleep. They fell asleep faster as they were more relaxed, and
they were not disturbed due to airway symptoms. Improving
sleep quality also has positive benefits for their daytime
activities. Consistent with the findings in this study, Price
et al. reported that patients with nighttime symptoms expe-
rienced more daytime breathlessness and a higher number
of exacerbations [21]. Conversely, patients in our study
using HFNC experienced reduced breathlessness and fewer
exacerbations, as well as reducing their nighttime symptoms.
The symptoms of breathlessness, fatigue and cough affect
patients in their daily activities and thereby have a major
impact on their quality of life [4,24–27]. In line with existing
research [2,28], we found that if patients reduced the
amount of morning symptoms, it not only improved their
physical ability but also their mental state during the day.
Several studies have demonstrated that patients considered
the morning symptoms of COPD as a key barrier to per-
forming their daily activities [1,2,29–31]. In a review by van
Bull et al. it was reported that morning symptoms were
associated with a sedentary lifestyle and therefore were nega-
tively related to physical activity [28]. In this present study,
patients woke up more energized and felt more positive.
Not having to start the day coughing resulted in more
energy to physical activities and to eat a proper breakfast.
Maintaining a social life is another important issue affect-
ing quality of life. Social isolation is a well-described prob-
lem among COPD patients [4,27,32]. In our study the
increased activity of daily living and a reduction of coughing
and sputum production seems to have a positive influence
on patients’ social life. Several patients and relatives
described how they were once again participating in social
activities, such as birthdays parties with their relatives. This
improvement could be explained by findings from COPD
studies reporting that COPD patients perceive visible
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symptoms such as breathlessness and cough as a barrier to
leaving their homes [4,27]. Some find coughing up mucus in
front of others to be repulsive and embarrassing, therefore
COPD symptoms can severely reduce their social interac-
tions. In a recent qualitative study patients also describe
they felt the need to explain and apologize when coughing
in public [27]. Other concerns around meal-related social
events could also be important. Eating and drinking are
often a natural part of a socializing culture, but this can be
another barrier for COPD patients. In a qualitative study,
Odencrants et al. investigated COPD patient’s experiences
with meal-related situations. Patients describe a recurrent
problem with having a dry mouth and cough, but also less
able to taste food was reported. Breathing and tiredness
were their main cause of problems, while coughing before
or during meals was their main concern [33]. With the
HFNC treatment, these cough related concerns and meal-
related problems have been reduced, which might explain why
patients’ experience a positive effect on their social behavior.
All participants in this study were adherent to treatment
as they used the device between 7 10 h/day. The technol-
ogy acceptance model (TAM) has earlier been used to
understand end-users accept of Health IT and Tele-medi-
cine. The model describes two main factors of importance
to acceptance of technology – ‘perceived usefulness’ and
‘perceived ease of use’ [34,35]. In this study all patients
described benefits of treatment and thereby its usefulness.
This was mainly because of the experienced effect on COPD
symptoms but also a belief in effect as described by one of
the patients. This patient explained that her belief in treat-
ment effect, built upon results from blood samples and the
feeling of security, were the reasons for her persistent use.
Former studies have presented an association between
patients’ belief in the necessity of medical treatment and
their treatment adherence [36,37].
The first five themes in our findings: Perceived lower
work of breathing; reduced COPD symptoms; improved qual-
ity of sleep; increased activity of daily living; feeling safe could
be related to patients’ perceiving the usefulness of the device
as they experienced an amelioration in their condition.
Former studies on LTOT have indicated side-effects and
trouble with equipment as barriers to adherence [13,14].
Kampelmacher et al. found discontent related to equipment
as the most common complaint amongst patients in LTOT
[14]. This is inconsistent with the findings from our study.
Participants – both patients and relatives – described the
device as easy to use, even for people without technical
skills, which according to TAM is promoting for acceptance
and actual use of the device. Furthermore, they did not
describe any side-effect from HFNC. Some patients, mainly
the day-time users, reported disadvantages related to immo-
bility issues. Former studies focusing on nurses’ acceptance
of new technologies have shown that if the usefulness of the
technology (e.g. treatment benefit) carries weight over the
disadvantages, the acceptance remains [38,39]. This might
explain the high level of acceptance and thereby adherence
among participants in this study.
Strengths and limitations of this study
This paper reports findings from a qualitative study with
twelve COPD patients and eight relatives. Patients were pur-
posively and conveniently sampled from a former RCT
study and may therefore not fully represent the diversity of
COPD patients, as they had to fit certain eligibility criteria.
To ensure a maximum variation sample within the inclusion
criteria we included both male and female, husbands, wives
and a daughter. As they were asked to participate at their
final visit, the majority of patients were persistent users of
HFNC. Three included patients were from the control group
in the former RCT study meaning they did not have any
experiences of HFNC use when asked about participating in
this study. As all patients included were adherent to treat-
ment, they may have been more positive and engaged in
treatment than those who discontinued use of HFNC during
the RCT study. Nevertheless, our findings provide important
insight into patients’ experiences with home treatment and
crucial aspects in relation to their treatment adherence.
As many of the patients had been treated for a longer
period when interviewed (mean 23months), they sometimes
experienced trouble remembering exactly how life was
before HFNC. Interviewing patients closer to initiation of
treatment might have reduced potential recall bias.
However, we believe the involvement of relatives was a valu-
able informative supplement as was including patients from
the control group who had been treated for a shorter period
at time of the interview. However, further research is needed
to detect reasons for patients to discontinue treatment in
order to obtain further understanding on how to meet these
patients and prevent non-adherence to treatment.
Conclusion
The patients in this study experienced symptom reduction
when treated with HFNC, including a perceived lower work
of breathing and less cough and sputum. Symptom reduc-
tion improved sleep quality, daytime activities, as well as the
ability to eat and socialize. Furthermore, important for
patients’ adherence is perceived usefulness and perceived
ease of use of the device
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